Understanding and treating chronic graft-versus-host disease and its lung form, bronchiolitis obliterans
Mechanisms and Therapy of Chronic Graft-vs.-Host Disease
This project works to find new treatments that block immune and metabolic drivers of chronic GVHD and bronchiolitis obliterans in people after allogeneic stem cell transplant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11174465 on NIH RePORTER |
What this research studies
You would be part of research aimed at why the immune system fails to tolerate donor cells after a transplant and how that leads to chronic GVHD and lung damage called BOS. Researchers will study patient blood and tissue samples alongside lab and animal work to look at T cell behavior and metabolism. They will test therapies that target those immune and metabolic pathways to try to stop inflammation and scarring in small airways. If eligible, you might be asked to give samples, have lung tests, or be offered experimental treatments at Dana-Farber or partner sites.
Who could benefit from this research
Good fit: Ideal candidates are people who have had an allogeneic hematopoietic stem cell transplant and have chronic GVHD, especially those with lung involvement (BOS) or high risk for BOS.
Not a fit: People without a history of allogeneic transplant or those with end-stage, irreversible lung scarring are unlikely to benefit from these approaches.
Why it matters
Potential benefit: If successful, the work could reduce or prevent progressive lung damage from BOS and lower long-term illness and deaths after transplant.
How similar studies have performed: Some drugs have shown benefit for cGVHD in prior trials, but targeting T-cell metabolism and specifically preventing or reversing BOS is a newer and less-tested strategy.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Cutler, Corey S — Dana-Farber Cancer Inst
- Study coordinator: Cutler, Corey S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.